Sanofi's Phase 2 atopic dermatitis trial of SAR444656 ends early, results posted

Sanofi had one notable update this week, a terminated Phase 2 trial with results now posted.

• A Phase 2, placebo-controlled trial of SAR444656 (also known as KT-474) in adults with moderate to severe atopic dermatitis was terminated due to sponsor decision, not related to a safety concern.¹ The study, sponsored by Sanofi with Kymera Therapeutics as a collaborator, had 70 participants enrolled¹ and used percent change from baseline in Eczema Area and Severity Index at Week 16¹ as its primary outcome. Results were first posted on 2026-11-03, with primary completion listed as 2025-10-23.